Login to Your Account



Financings Roundup

Blend Gets $16M in Series B; Brewing Platinum Nano-Drug

By Randy Osborne
Staff Writer

Wednesday, December 19, 2012
With a new CEO and $16 million in Series B money, combination-drug developer Blend Therapeutics Inc. is putting oomph behind a platinum-based therapy – a new chemical entity unto itself – to be made with the company's nanoparticle technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription